1 research call since Oct 14. Latest view: Neutral
Last close
$271.04 2026-10-28
1 week
+5.1%
1 month
-0.3%
3 months
+2.1%
1 year
+47.5%
Latest call vs SPY
+9.8% since 2026-10-13
Next earnings
2027-01-26 AMC
Technical scan
Strong Buy rank 15 of 127
Price, last 12 months daily close · markers are published calls
Current technical signals nightly scan, 2026-10-28
MACD: Bullish MomentumOBV: Confirmed Uptrend
Notable moves days JNJ was among the market's biggest movers
2026-10-13-5.7% Morning earnings beat · $248.61
What would change the latest view
If FY27 consensus EPS of $12.26 is cut materially (e.g., below ~$11.80) after Q4 earnings, the 'trough year' thesis fails and the multiple likely compresses further
If the talc participation threshold is not met or the deal collapses, the de-risking leg of the bull case is void
If Darzalex misses consensus again in Q4, treat the Q3 miss as trend, not noise
If the stock holds above ~$260 on no new fundamental news within 3 months, the flush was purely technical and the dip-buy thesis worked
JNJ delivered a genuine operational beat (6% operational sales growth, Tremfya +68%, raised guidance) but the market correctly identified quality issues: Darzalex decelerating (+16% but below consensus), Stelara erosion (-54%), a MedTech sales miss, and Innovative Medicine margin collapsing from 44.3% to 35.4% on acquired IPR&D and mix. The guidance 'raise' only partially…
Entry $248.61 (2026-10-13)1m vs SPY: +9.8%so far
Want a fresh deep analysis on JNJ?
We analyze it in depth and publish here, usually within about 5 minutes; leave an email and we tell you when it is ready.